| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Carcinogenesis |
Department of Cancer Cell Biology [T. H., H. H. N., T. D. S. A., K. T. K.] and Occupational Health Program [D. C. C.], Harvard School of Public Health, Boston, Massachusetts 02115; Thoracic Surgery Unit, Department of Surgery [J. C. W.], Department of Pathology [E. J. M.], and Pulmonary and Critical Care Unit, Department of Medicine [D. C. C.], Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114; and Laboratory for Molecular Epidemiology, Department of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, California 94143 [J. K. W.]
The short arm of chromosome 3 is thought to harbor a novel oncogenic locus that is important in the genesis of lung cancer. The region at 3p21 is believed to contain a distinct locus that is sensitive to loss from the action of tobacco smoke carcinogens and has been reported to be specifically targeted for deletion in lung cancer. To investigate whether 3p21 alteration in lung cancer is associated with carcinogen exposure, PCR-based analysis was performed to detect loss of heterozygosity (LOH) on chromosome 3 at 3p21 in non-small cell lung carcinoma (NSCLC). We also measured instability at the BAT-26 locus, because the mismatch DNA repair gene, hMLH1, is found at 3p21. LOH at 3p21 was analyzed for association with the clinical features of NSCLC, p53 mutation status, polynuclear aromatic hydrocarbon-DNA adduct levels (measured using 32P-postlabeling) and carcinogen exposure information including cigarette smoking and asbestos exposure. Of 219 lung cancers, 150 cases (68.5%) were informative at the D3S1478 locus, and 44.2% of squamous cell carcinoma cases and 30.2% of adenocarcinoma cases showed 3p21 LOH. None of the cancers showed BAT-26 instability. The prevalence of 3p21 LOH was higher in both current and former smokers compared with never smokers and was higher in p53 mutated cases. Among squamous cell carcinoma cases, there was a strong association of increased 3p21 LOH with increasing polynuclear aromatic hydrocarbon-DNA adducts levels (P = 0.03), as well as an increased prevalence LOH with earlier age of smoking initiation (P = 0.02). Our results confirm that 3p21 LOH is strongly associated with measures of biologically effective dose of exposure to tobacco carcinogens. Our results also suggest that alterations of hMLH1 are not related to any of the reported associations, because there was no evidence of microsatellite instability. Finally, LOH in 3p21 may be an early molecular event in NSCLC, because it is significantly associated with a tendency to start smoking at a young age.
This article has been cited by other articles:
![]() |
S. Aldington, M. Harwood, B. Cox, M. Weatherall, L. Beckert, A. Hansell, A. Pritchard, G. Robinson, R. Beasley, and on behalf of the Cannabis and Respiratory Disease Cannabis use and risk of lung cancer: a case-control study Eur. Respir. J., February 1, 2008; 31(2): 280 - 286. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. W. Thurston, G. Liu, D. P. Miller, and D. C. Christiani Modeling Lung Cancer Risk in Case-Control Studies Using a New Dose Metric of Smoking Cancer Epidemiol. Biomarkers Prev., October 1, 2005; 14(10): 2296 - 2302. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Alberg, M. V. Brock, and J. M. Samet Epidemiology of Lung Cancer: Looking to the Future J. Clin. Oncol., May 10, 2005; 23(14): 3175 - 3185. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Marsit, M. Hasegawa, T. Hirao, D.-H. Kim, K. Aldape, P. W. Hinds, J. K. Wiencke, H. H. Nelson, and K. T. Kelsey Loss of Heterozygosity of Chromosome 3p21 Is Associated with Mutant TP53 and Better Patient Survival in Non-Small-Cell Lung Cancer Cancer Res., December 1, 2004; 64(23): 8702 - 8707. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Knoke, T. G. Shanks, J. W. Vaughn, M. J. Thun, and D. M. Burns Lung Cancer Mortality Is Related to Age in Addition to Duration and Intensity of Cigarette Smoking: An Analysis of CPS-I Data Cancer Epidemiol. Biomarkers Prev., June 1, 2004; 13(6): 949 - 957. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Danesi, F. De Braud, S. Fogli, T. M. De Pas, A. Di Paolo, G. Curigliano, and M. Del Tacca Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer Pharmacol. Rev., March 1, 2003; 55(1): 57 - 103. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |